Dougados M, Barret P, Menkes C J, Amor B
Clinique de Rhumatologie, Hôpital Cochin, Paris.
Ann Med Interne (Paris). 1987;138(8):595-8.
In 11 patients suffering from polymyalgia rheumatica or Horton's disease, dapsone was associated with corticotherapy because of corticosteroid side effects (11 cases) and/or progression of the disease despite relatively high dose steroid therapy (6 cases). This treatment had to be discontinued in 4 patients because of side effects and in 3 patients because of a recurrence of the disease. Despite these numerous withdrawals, dapsone seems to be of clinical benefit in these patients because of 1) the mildness of the side effects observed in this study, 2) its efficacy evaluated on the improvement of clinical signs of the disease and, overall, on the decrease in the corticosteroid consumption.
在11例患有风湿性多肌痛或霍顿病的患者中，由于皮质类固醇的副作用（11例）和/或尽管使用了相对高剂量的类固醇治疗但疾病仍进展（6例），氨苯砜与皮质激素疗法联合使用。4例患者因副作用不得不停药，3例患者因疾病复发停药。尽管有多次停药情况，但氨苯砜似乎对这些患者有临床益处，原因如下：1）本研究中观察到的副作用较轻；2）其疗效通过疾病临床症状的改善以及总体上皮质类固醇用量的减少来评估。
